 |
" |
Home > Research, Discovery & Progress > Program Overview
updated 01/11/2013
Three cores support Prostate SPORE research and development projects:
- Administration
- Biostatistics
- Tissue / Informatics
Contact:
Jill Miller, Administrator
Phone: (734) 998-6761
jsmiller@umich.edu
Core Director: Kenneth J. Pienta, M.D.
Core Co-PI: James E. Montie, M.D. / Ganesh Palapattu, M.D.
Core Co-PI: Kathleen A. Cooney, M.D.
Core Co-PI: Evan T. Keller, D.V.M., Ph.D.
The University of Michigan Comprehensive Cancer Center (UMCCC) Prostate SPORE administrative core is responsible for leadership, guidance and management. The administrative core oversees all aspects and performs numerous duties across the expansive scope of the SPORE to support the translationalgoals of the investigators. The Prostate SPORE Administration Core is guided by the following Specific Aims:
Specific Aim 1: Provide scientific, programmatic and administrative leadership to all aspects of the SPORE. Effective Administration Core leadership is essential to the success of the SPORE. The Administration Core is the central decision-making group designed to encourage research productivity, promote interaction and collaboration and set direction and priorities for the SPORE.
Specific Aim 2: Develop, facilitate and monitor progress of translational aims with project co-leaders. The Clinical Applications Committee, the annual review with the External Advisory Board and Steer Committee and the monthly meetings between project leaders and the SPORE PI all function to keep the SPORE robust and move the translational objectives forward. All of these interactions are facilitated by the Administration Core.
Specific Aim 3: Identify, support, and facilitate scientific collaborations. The Administration Core is charged with creating a culture of collaboration through initiating and implementing successful collaborations. Formal horizontal and vertical collaborations are encouraged to accomplish research progress and move promising SPORE projects to the next step on the translational / clinical development pathway.
Specific Aim 4: Facilitate communication. Thorough communication is crucial to the SPORE's success. The Administration Core is responsible for facilitating communication between investigators and groups within the Prostate SPORE as well as with UM SPOREs, the SPORE network outside UM, NCI and investigators across the spectrum of translational cancer research.
Specific Aim 5: Perform fiscal and data management functions. The Core performs financial management for each project, core and development project. The Core also oversees data management, an essential component of excellent clinical research.
Specific Aim 6: Provide functional and ethical oversight to projects and cores. The Core provides support and oversight to ensure that all investigators have IRB and animal approvals in place to conduct research. The Core coordinates quality assurance between the tissue banks and clinical databases.
The Administration Core (AC) Director, Dr. Kenneth Pienta, guides and facilitates overall direction of the SPORE and oversees the research projects. Dr. Kathleen Cooney, as co-leader, oversees all cores and developmental programs. During this period of transition, Drs. Montie and Palapattu in the role as co-leader oversee the translational components and assures the translational objectives are met. They also direct the Clinical Applications Committee. Jill Miller as Administrative Director coordinates the day-to-day SPORE operations. Dr. Evan Keller assists with core management and facilitates project progress.
Return to top
Contact:
Core Director: Alexander Tsodikov, Ph.D.
Phone: (734) 936-9580
tsodikov@umich.edu
The goal of the Biostatistics Core is to collaborate with SPORE investigators and other core resource scientists to enhance the quality of the research undertaken in the University of Michigan Prostate SPORE. The Core personnel have been chosen because of their expertise in relevant areas of Biostatistics and Bioinformatics that is specifically required for the SPORE projects to succeed. Support will be provided in all stages of the research, beginning with the formulation of the research question, through the experimental design stage and data collection stage, to data analysis and interpretation, to the writing of reports and dissemination of results. It will be apparent from this proposal that Core personnel have played a significant role in designing the proposed experiments and in planning the data analysis. The exact nature of the collaboration will depend on the specifics of the science and the needs of the project. In addition to direct support of the projects and other cores, senior statisticians will also focus on statistical methodology development related to the needs of prostate cancer research in this SPORE. Thus the Specific Aims of the Core are:
- Assist investigators in the design of clinical and laboratory experiments;
- Assist investigators in the analysis and interpretation of data from clinical and laboratory experiments and in writing of manuscripts relaying prostate cancer SPORE results to the scientific community; and
- Undertake translational biostatistics research to develop methodology and software implementation relevant to prostate cancer.
Our ultimate goal is to decrease the morbidity and mortality of prostate cancer through innovative research that is supported by rigorous biostatistical design and support.
Return to top
Related Publications:
-
Comstock KE, Hall CL, Daignault S, Mandlebaum SA, Yu C, Keller ET: "A bioluminescent orthotopic mouse model of human osteosarcoma that allows sensitive and rapid evaluation of new therapeutic agents In vivo." In Vivo, 23(5):661-8, 2009. PMID: 19779098. PMCID: In process.
-
Kunju LP, Daignault S, Wei JT, Shah RB: "Multiple prostate cancer cores with different Gleason grades submitted in the same specimen container without specific site designation: should each core be assigned an individual Gleason score? "Human Pathol, 40(4): 558-564, 2009. PMID: 19144380. PMCID: In process
-
Piert M, Park H, Khan A, Sddiqui J, Hussain H, Chenevert T, Wood D, Johnson TD, Shah RB, Meyer C: "Detection of aggressive primary prostate cancer with 11C-Choline PET/CT utilizing multi-modality fusion techniques."Journal of Nuclear Medicine, 50:1585-1593, 2009. PMCID: PMC2837847.
-
Weizer AZ, Wasco MJ, Wang R, Daignault S, Lee CT, Shah RB: "Multiple adverse histological features increase the odds of under staging T1 bladder cancer. “ J Urol. 182(1):59-65, 2009. PMID: 19447443. PMCID: In process.
-
Hu M, Yu J, Taylor JMG, Chinnaiyan A, Qin Z: "On the Detection and Refinement of Transcription Factor Binding Sites Using ChIP-Seq Data." Nucleic Acids Research, 1-14, 2010. PMID: 20056654. PMCID: PMC2853110.
-
Wasco MJ, Daignault S, Bradley D, Shah RB: "Nested variant of urothelial carcinoma: a clinicopathologic and immunohistochemical study of 30 pure and mixed cases. "Hum Pathol. 2010 Feb;41(2):163-71. PMID: 19800100. PMCID: In process.
Return to top
Contact:
Core Director: Arul Chinnaiyan, M.D., Ph.D.
Co-Core Director: Pryia Kunju, M.D.
Core Technical Director: Javed Siddiqui, M.S.
Phone: 734-764-3732
Email: siddiqui@umich.edu
The continued goal of Prostate SPORE Tissue/Informatics Core is to collect biological material with associated clinical information to facilitate translational research. The Tissue Core places patient confidentiality and clinical care as a top priority. As a coordinated effort between pathology, urology, medical oncology, and SPORE researchers, the Core has a developed a unified bioinformatics infrastructure that provides researchers a wide range of annotated samples. To date, detailed information exists on over 4200 radical prostatectomy patients operated on at the Univ. of Michigan between 1994-present. The specific goals of the Tissue Core include:
(1) Protection of patient welfare. The highest priority is given to assure that no research protocol compromises pathology diagnosis or tumor staging.
(2) Acquisition and processing of prostate tissues for research. The Core assures that the widest range of prostate tissues and derived biomolecules (i.e., protein, DNA and RNA) are available from several established and new sources. These include benign prostate tissue from patients without any known prostatic disease (cystoprostatectomy specimens and transplant donor prostates), clinically localized prostate cancer, and metastatic hormone refractory prostate cancer (Rapid Autopsy Program).
(3) Maintenance of clinical and pathology data with links to molecular studies. The Tissue/Informatics Core will continue to expand the detailed clinical and pathology database conforming to the NCI's Common Data Elements (CDE) guidelines, permitting queries between molecular findings and clinically relevant outcomes.
(4) High quality pathologic review of prostate tissues. Expert GU pathologists assure uniform review of prostate tissue samples.
(5) Pathology consultation for the purpose of designing translational research projects. This service focuses on determining the types of tissues and amount required for the successful completion of the projects.
(6) Quality assessment of prostate tissues and clinical data. The Tissue Core staff regularly evaluates frozen and formalin fixed tissues for adequacy.
(7) Development of technology appropriate for pathology based translational research. New technologies such as genome and transcriptome sequencing to identify causative, driving mutations are being introduced. The Tissue Core will continue to be integral to the sample preparation, analysis of biopsy tissue tumor content and long-term storage of all these patient samples. In summary, the Tissue Core will provide SPORE investigators with a wealth of carefully annotated samples for translational research, while maintaining the highest level of clinical care and patient confidentiality.
Return to top
Related Publications:
- Shiozawa Y, Pedersen EA, Patel LR, Ziegler AM, Havens AM, Jung Y, Wang J, Zalucha S, Loberg RD, Pienta KJ, Taichman RS. GAS6/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche. Neoplasia. 2010 Feb;12(2):116-27. PMCID: PMC2814350
- Brenner JC, Chinnaiyan AM. Translocations in epithelial cancers. Biochim Biophys Acta. 2009 Dec;1796(2):201-15. PMCID: PMC2752494
- Ray AM, Zuhlke KA, Johnson GR, Levin AM, Douglas JA, Lange EM, Cooney KA. Absence of truncating BRIP1 mutatios in chromosome 17q-linked hereditary prostate cancer families. Br J Cancer. 2009 Dec 15;101(12):2043-7. PMCID: PMC2795448
- Roca H, Varsos ZS, Pienta KJ. CCL2 is a negative regulator of AMP-activated protein kinase to sustain mTOR complex-1 activation, survivin expression, and cell survival in human prostate cancer PC3 cells. Neoplasia. 2009 Dec;11(12):1309-17. PMCID: PMC2794512
- Roca H, Varsos ZS, Sud S, Craig MJ, Ying C, Pienta KJ. CCL2 and interleukin-6 promote survival of human CD11b+ peripheral blood mononuclear cells and induce M2-type macrophage polarization. J Biol Chem. 2009 Dec 4;284(49):34342-54. PMCID: PMC2797202
- Yu S, Qin D, Shangary S, Chen J, Wang G, Ding K, McEachern D, Qiu S, Nikolovska-Coleska Z, Miller R, Kang S, Yang D, Wang S. Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction. J Med Chem. 2009 Dec 24;52(24):7970-3. PMCID: PMC2795799
- Mani RS, Tomlins SA, Callahan K, Ghosh A, Nyati MK, Varambally S, Palanisamy N, Chinnaiyan AM. Induced chromosomal proximity and gene fusions in prostate cancer. Science. 2009 Nov 27;326(5957):1230. PMCID: PMC2935583.
- Barthel SR, Wiese GK, Cho J, Opperman MJ, Hays DL, Siddiqui J, Pienta KJ, Furie B, Dimitroff CJ. Alpha 1,3 fucosyltransferases are master regulators of prostate cancer cell trafficking. Proc Natl Acad Sci U S A. 2009 Nov 17;106(46):19491-6. PMCID: PMC2780742
- Mizutani K, Sud S, McGregor NA, Martinovski G, Rice BT, Craig MJ, Varsos ZS, Roca H, Pienta KJ. The chemokine CCL2 increases prostate tumor growth and bone metastasis through macrophage and osteoclast recruitment. Neoplasia. 2009 Nov;11(11):1235-42. PMCID: PMC2767225
- Vellaichamy A, Sreekumar A, Strahler JR, Rajendiran T, Yu J, Varambally S, Li Y, Omenn GS, Chinnaiyan AM, Nesvizhskii AI. Proteomic interrogation of androgen action in prostate cancer cells reveals roles of aminoacyl tRNA synthetases. PLoS One. 2009 Sep 18;4(9):e7075. PMCID: PMC2740864
- Wang R, Chinnaiyan AM, Dunn RL, Wojno KJ, Wei JT. Rational approach to implementation of prostate cancer antigen 3 into clinical care. Cancer. 2009 Sep 1;115(17):3879-86. PMCID: PMC2746943
- Piert M, Park H, Khan A, Siddiqui J, Hussain H, Chenevert T, Wood D, Johnson T, Shah RB, Meyer C. Detection of aggressive primary prostate cancer with 11C-choline PET/CT using multimodality fusion techniques. J Nucl Med. 2009 Oct;50(10):1585-93. PMCID: PMC2837847
- Han B, Mehra R, Suleman K, Tomlins SA, Wang L, Singhal N, Linetzky KA, Palanisamy N, Zhou M, Chinnaiyan AM, Shah RB. Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma. Mod Pathol. 2009 Sep;22(9):1176-85. PMCID: PMC2760291
- Han B, Mehra R, Lonigro RJ, Wang L, Suleman K, Menon A, Palanisamy N, Tomlins SA, Chinnaiyan AM, Shah RB. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod Pathol. 2009 Aug;22(8):1083-93. PMCID: PMC2760294
- Mizutani K, Roca H, Varsos Z, Pienta KJ. Possible mechanism of CCL2-induced Akt activation in prostate cancer cells. Anticancer Res. 2009 Aug;29(8):3109-13.PMID: 19661323
- Maher CA, Palanisamy N, Brenner JC, Cao X, Kalyana-Sundaram S, Luo S, Khrebtukova I, Barrette TR, Grasso C, Yu J, Lonigro RJ, Schroth G, Kumar-Sinha C, Chinnaiyan AM. Chimeric transcript discovery by paired-end transcriptome sequencing. Proc Natl Acad Sci U S A. 2009 Jul 28;106(30):12353-8. PMCID: PMC2708976
- Ray AM, Zuhlke KA, Levin AM, Douglas JA, Cooney KA, Petros JA. Sequence variation in the mitochondrial gene cytochrome c oxidase subunit I and prostate cancer in African American men. Prostate. 2009 Jun 15;69(9):956-60. PMCID: PMC2729404
Return to top
|
|
  
Adjust text size
|
|
